keyword
MENU ▼
Read by QxMD icon Read
search

faecal calprotectin in ulcerative colitis

keyword
https://www.readbyqxmd.com/read/29726893/the-effect-of-vitamin-d-on-intestinal-inflammation-and-faecal-microbiota-in-patients-with-ulcerative-colitis
#1
Mayur Garg, Philip Hendy, John Nik Ding, Sophie Shaw, Georgina Hold, Ailsa Hart
Background and Aims: There is evidence vitamin D may be immunomodulatory and alter faecal microbiota, but results from clinical studies in humans to date have been inconclusive. This study aimed to assess the effect of vitamin D replacement in vitamin D deficient patients with and without ulcerative colitis (UC) on inflammation and faecal microbiota. Methods: Vitamin D was replaced over 8 weeks in patients with active UC (defined by faecal calprotectin ≥100 µg/g), inactive UC (faecal calprotectin <100 µg/g), and non-IBD controls with baseline 25(OH) vitamin D <50 nmol/L, and markers of inflammation and faecal microbiota analysed...
May 3, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29550798/serum-neutrophil-gelatinase-associated-lipocalin-ngal-correlates-with-clinical-and-endoscopic-activity-in-ulcerative-colitis-but-fails-to-predict-activity-in-crohn-s-disease
#2
A Budzynska, M Gawron-Kiszka, E Nowakowska-Dulawa, J Spiewak, M Lesinska, M Kukla, M Waluga, M Hartleb
Serum neutrophil gelatinase-associated lipocalin (NGAL) is a low molecular weight protein released from activated neutrophils and intestine epithelium whose mRNA expression is increased in inflamed intestinal tissue. The purpose of this study was to explore the relationship between serum NGAL level and activity of inflammatory bowel diseases. A total of 120 patients, 79 with Crohn's disease (CD) and 41 with ulcerative colitis (UC) were prospectively included into the study. Serum NGAL was measured by ELISA...
December 2017: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/29484157/can-faecal-calprotectin-predict-relapse-in-inflammatory-bowel-disease-a-mini-review
#3
REVIEW
T S Chew, J C Mansfield
Crohn's disease and ulcerative colitis are chronic inflammatory disorders affecting the gastrointestinal tract. Faecal calprotectin is a protein complex of the S-100 family of calcium-binding proteins present in inflammatory cells that can be measured in stool samples, which act as a biomarker for bowel inflammation. Elevated faecal calprotectin has been shown to reflect the presence of ongoing mucosal inflammation, which improves with mucosal healing. The aim of this review was to evaluate the available evidence on the ability of faecal calprotectin to predict a relapse in inflammatory bowel disease...
January 2018: Frontline Gastroenterology
https://www.readbyqxmd.com/read/29383026/factors-affecting-clinical-decision-making-in-inflammatory-bowel-disease-and-the-role-of-point-of-care-calprotectin
#4
Yannick Derwa, Christopher J M Williams, Ruchit Sood, Saqib Mumtaz, M Hassan Bholah, Christian P Selinger, P John Hamlin, Alexander C Ford, David J Gracie
Objectives: Patient-reported symptoms correlate poorly with mucosal inflammation. Clinical decision-making may, therefore, not be based on objective evidence of disease activity. We conducted a study to determine factors associated with clinical decision-making in a secondary care inflammatory bowel disease (IBD) population, using a cross-sectional design. Methods: Decisions to request investigations or escalate medical therapy were recorded from outpatient clinic encounters in a cohort of 276 patients with ulcerative colitis (UC) or Crohn's disease (CD)...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29379609/protocol-for-a-multicentred-randomised-controlled-trial-investigating-the-use-of-personalised-golimumab-dosing-tailored-to-inflammatory-load-in-ulcerative-colitis-the-goal-arc-study-glm-dose-optimisation-to-adequate-levels-to-achieve-response-in-colitis-led
#5
Juliette Sheridan, Carol Ann Coe, Peter Doran, Laurence Egan, Garret Cullen, David Kevans, Jan Leyden, Marie Galligan, Aoibhlinn O'Toole, Jane McCarthy, Glen Doherty
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimumab (GLM). Several recent retrospective and prospective studies have demonstrated that fixed dosing schedules of anti-TNF agents often fails to consistently achieve adequate circulating therapeutic drug levels (DL) with consequent risk of immunogenicity treatment failure and potential risk of hospitalisation and colectomy in patients with UC...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29373727/determinants-of-reduced-genetic-capacity-for-butyrate-synthesis-by-the-gut-microbiome-in-crohn-s-disease-and-ulcerative-colitis
#6
Emilio J Laserna-Mendieta, Adam G Clooney, Julián F Carretero-Gomez, Carthage Moran, Donal Sheehan, James A Nolan, Colin Hill, Cormac G M Gahan, Susan A Joyce, Fergus Shanahan, Marcus J Claesson
Background and Aims: Alterations in short chain fatty acid metabolism, particularly butyrate, have been reported in inflammatory bowel disease, but results have been conflicting because of small study numbers and failure to distinguish disease type, activity or other variables such as diet. We performed a comparative assessment of the capacity of the microbiota for butyrate synthesis, by quantifying butyryl-CoA:acetate CoA-transferase [BCoAT] gene content in stool from patients with Crohn's disease [CD; n = 71], ulcerative colitis [UC; n = 58] and controls [n = 75], and determined whether it was related to active vs inactive inflammation, microbial diversity, and composition and/or dietary habits...
January 24, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29310593/how-disease-extent-can-be-included-in-the-endoscopic-activity-index-of-ulcerative-colitis-the-panmayo-score-a-promising-scoring-system
#7
Anita Bálint, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Mónika Szűcs, László Tiszlavicz, Renáta Bor, Ágnes Milassin, Mariann Rutka, Anna Fábián, Tamás Molnár
BACKGROUND: Colonoscopy plays crucial role in the establishment of the diagnosis, management and follow-up of ulcerative colitis (UC). None of the currently widely used endoscopic scores consider disease extent, and therefore do not correlate with the real severity of UC. Our aim was to assess the accuracy of a new score, the Pancolonic Modified Mayo Score that can reflect not only the severity, but the extent of active UC. METHODS: One hundred and four UC patients were enrolled in this prospective study...
January 8, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29207381/alicaforsen-an-antisense-inhibitor-of-intercellular-adhesion-molecule-1-in-the-treatment-for-left-sided-ulcerative-colitis-and-ulcerative-proctitis
#8
Thomas Greuter, Stephan R Vavricka, Luc Biedermann, Julia Pilz, Jan Borovicka, Frank Seibold, Bernhard Sauter, Gerhard Rogler
BACKGROUND: Data on the efficacy of intercellular adhesion molecule-1 antisense oligonucleotide alicaforsen in ulcerative colitis (UC) is inconsistent. METHODS: All patients, who had received at least one dose of alicaforsen, were analyzed retrospectively. Alicaforsen's efficacy was assessed in patients treated for left-sided UC and proctitis by comparing clinical and (if applicable) endoscopic disease activity before/after treatment. RESULTS: Twelve patients were treated for left-sided UC or proctitis...
2018: Digestive Diseases
https://www.readbyqxmd.com/read/29186372/irritable-bowel-like-symptoms-in-ulcerative-colitis-are-as-common-in-patients-in-deep-remission-as-in-inflammation-results-from-a-population-based-study-the-ibsen-study
#9
Magne Henriksen, Marte Lie Høivik, Lars-Petter Jelsness-Jørgensen, Bjørn Moum
Background and Aims: An increased prevalence of irritable bowel syndrome [IBS]-like symptoms has been reported in patients with ulcerative colitis [UC]. Whether ongoing inflammation increases the prevalence of such symptoms is unknown. The aims of this study were to determine the prevalence of IBS-like symptoms in a population-based cohort of UC patients 20 years after diagnosis, and to assess the possible association between such symptoms and ongoing inflammation. Methods: Patients diagnosed with UC between 1990 and 1994, in a geographically well-defined area, were included in a prospective follow-up study, and IBS symptoms according to Rome III criteria were recorded 20 years after diagnosis...
March 28, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29121178/exploration-of-predictive-biomarkers-of-early-infliximab-response-in-acute-severe-colitis-a-prospective-pilot-study
#10
Lauren Beswick, Ourania Rosella, Gennaro Rosella, Belinda Headon, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg
Background: The outcomes of acute severe ulcerative colitis [ASUC] appear to be dependent on early intervention with the first and/or further infliximab [IFX] doses, although parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early after IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited inpatients with steroid-refractory ASUC, who then received 1-3 IFX rescue doses [5 mg/kg per dose] at the discretion of the treating clinician...
February 28, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28932267/clinical-performance-of-an-infliximab-rapid-quantification-assay
#11
Fernando Magro, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Tânia Meira, Patrícia Andrade, João-Bruno Soares, Diana Carvalho, Paula Sousa, Ana Isabel Vieira, Joanne Lopes, Cláudia Camila Dias, Karel Geboes, Fátima Carneiro
BACKGROUND: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients. This study aimed to explore a rapid IFX-quantification test from a clinical perspective. METHODS: This manuscript describes a prospective cohort study involving 110 ulcerative colitis (UC) patients on the maintenance phase of IFX. IFX trough levels were quantified using a rapid quantification assay and a commonly-used reference kit...
September 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28881876/accuracy-of-faecal-immunochemical-test-to-predict-endoscopic-and-histological-healing-in-ulcerative-colitis-a-prospective-study-based-on-validated-histological-scores
#12
COMPARATIVE STUDY
Hai Yun Shi, Francis K L Chan, Anthony W H Chan, Akira Higashimori, Moe Kyaw, Jessica Y L Ching, Arthur K C Luk, Sunny H Wong, Justin C Y Wu, Joseph J Y Sung, Siew C Ng
Background and Aims: Endoscopic and histological healing are associated with improved clinical outcomes in ulcerative colitis [UC]. We aimed to investigate the predictive value of faecal immunochemical test [FIT] for endoscopic and histological healing in UC. Methods: We measured quantitative FIT and faecal calprotectin [FC] in 140 consecutive UC patients who underwent colonoscopy. We assessed the diagnostic accuracy of FIT for predicting endoscopic healing using the Mayo endoscopic subscore [MES 0/1] and for histological healing using the Geboes score [< 2...
September 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28844038/unrestricted-faecal-calprotectin-testing-performs-poorly-in-the-diagnosis-of-inflammatory-bowel-disease-in-patients-in-primary-care
#13
Samantha Conroy, Melissa F Hale, Simon S Cross, Kirsty Swallow, Reena H Sidhu, Ravishankar Sargur, Alan J Lobo
BACKGROUND: Faecal calprotectin (FC) measurement distinguishes patients with inflammatory bowel disease (IBD) from those with irritable bowel syndrome but evidence of its performance in primary care is limited. AIMS: To assess the yield of IBD from FC testing in primary care. METHODS: Retrospective review of hospital records to assess the outcome following FC testing in primary care. Investigations for all patients undergoing FC testing in a single laboratory for 6 months from 1 October 2013 to 28 February 2014 were reviewed...
August 26, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28815032/pain-may-be-an-important-factor-to-consider-in-inflammatory-bowel-disease-patients-troubled-by-fatigue
#14
Lars-Petter Jelsness-Jørgensen, Svein-Oskar Frigstad, Bjørn Moum, Tore Grimstad, Randi Opheim, Jørgen Jahnsen, Tomm Bernklev
BACKGROUND: Pain has been associated with fatigue in many chronic diseases, but data are not available for inflammatory bowel disease (IBD). The aim of this study was to investigate whether fatigue is associated with pain in IBD after adjusting for the relevant covariates. METHODS: Participants were recruited from nine hospitals in the south-eastern and western part of Norway. Socio-demographic variables were self-reported by patients. Disease activity was assessed by disease activity indices and faecal calprotectin...
August 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28790099/gsk2586184-a-jak1-selective-inhibitor-in-two-patients-with-ulcerative-colitis
#15
Leonie C S De Vries, Valerie J Ludbrook, Kirsty J Hicks, Geert R D'Haens
Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC). Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Adverse events including neutropenia and anaemia resulting from JAK2 inhibition have been observed in actively treated patients. By selectively targeting JAK1, such adverse events could be expected to be avoided. This open label study was designed to enrol 15 patients with UC, however the trial was discontinued after two inclusions due to safety concerns with the agent in a parallel trial for systemic lupus erythematosus...
August 7, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28735301/effect-of-faecal-calprotectin-assay-variability-on-the-management-of-inflammatory-bowel-disease-and-potential-role-of-faecal-s100a12
#16
COMPARATIVE STUDY
Simon John Whitehead, Clare Ford, Rousseau Mariano Gama, Ala Ali, Brian McKaig, Jenna Louise Waldron, Helen Steed, Matthew James Brookes
AIMS: To prospectively evaluate whether between-assay variability of different faecal calprotectin (f-Cp) assays influences diagnostic accuracy for inflammatory bowel disease (IBD) in a cohort of patients with confirmed IBD and irritable bowel syndrome (IBS). To also evaluate the diagnostic accuracy of faecal S100A12 (f-S100A12) against f-Cp in the same patient cohort and assess whether f-S100A12 offers additional diagnostic value. METHODS: F-Cp using four commercially available f-Cp assays, f-S100A12 and blood biomarkers were measured in patients, recruited from the local IBD clinic, who had established IBS or active ulcerative colitis (UC) and Crohn's disease (CD)...
December 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28651829/evaluation-of-a-12-week-targeted-vitamin-d-supplementation-regimen-in-patients-with-active-inflammatory-bowel-disease
#17
Mayur Garg, Ourania Rosella, Gennaro Rosella, Yunqiu Wu, John S Lubel, Peter R Gibson
BACKGROUND & AIMS: Vitamin D at serum 25(OH)D concentrations above 100 nmol/L is associated with disease remission in patients with IBD, suggesting targeted dosing might be anti-inflammatory. This study aimed to assess the effectiveness, safety and predictors of a 12-week regimen of vitamin D supplementation to achieve such a target in patients with active disease. METHODS: In a pilot study, patients with active colitis and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100-125 nmol/L...
June 15, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28618062/examining-maintenance-care-following-infliximab-salvage-therapy-for-acute-severe-ulcerative-colitis
#18
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel Van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
BACKGROUND AND AIM: Data supporting the optimal maintenance drug therapy and strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance and monitoring strategies employed in patients post-IFX induction therapy. METHODS: Patients in six Australian tertiary centers treated with IFX for steroid-refractory ASUC between April 2014 and May 2015 were identified via hospital IBD and pharmacy databases...
January 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28362144/long-term-effectiveness-of-vedolizumab-in-inflammatory-bowel-disease-a-national-study-based-on-the-swedish-national-quality-registry-for-inflammatory-bowel-disease-swibreg
#19
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk, Michael Eberhardson, Pontus Karling, Charlotte Söderman, Pär Myrelid, Yang Cao, Daniel Sjöberg, Mari Thörn, Per Karlén, Erik Hertervig, Hans Strid, Jonas F Ludvigsson, Sven Almer, Jonas Halfvarson
OBJECTIVES: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness. MATERIALS AND METHODS: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28333288/exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#20
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis [UC] or Crohn's disease [CD] has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 [Caverage] as exposure measure...
August 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
48306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"